In this article, we will discuss Glasdegib (Dosage Overview). So, let’s get started.
Glasdegib is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.
Recommended Dose and Schedule
The recommended dose of Glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of each 28-day cycle in the absence of
unacceptable toxicity or loss of disease control. For patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response.
Administer Glasdegib with or without food. Do not split or crush Glasdegib tablets.
Administer Glasdegib about the same time each day. If a dose of Glasdegib is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of Glasdegib is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose.
Return to the normal schedule the following day. Do not administer 2 doses of Glasdegib within 12 hours.